Immunic Hosts RMS R&D Day, Reaffirms ENSURE Top-Line Data by Year-End 2026
IMUX has more than doubled off its 52-week low of $5.062 on elevated volume (2.0× avg).
Summary
Immunic hosted an R&D Day for its lead MS drug, vidofludimus calcium, reaffirming top-line Phase 3 ENSURE data by end of 2026 and outlining a path to NDA submission in mid-2027.
Key Events · Product Development and Regulatory · IMUX
-
RMS R&D Day Presentation
Immunic hosted a Relapsing MS R&D Day on September 9, 2026, presenting detailed clinical, preclinical, and commercial data for vidofludimus calcium (IMU-838).
-
ENSURE Top-Line Data by Year-End
The presentation reaffirmed that top-line data from the fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials are expected by the end of 2026.
-
Regulatory Pathway Outlined
Immunic targets an NDA submission in mid-2027, with potential U.S. regulatory approval in 2028, contingent on positive ENSURE results.
-
Progressive MS R&D Day Announced
A separate Progressive MS R&D Day is scheduled for November 5, 2026, to discuss the CALLIPER trial and Phase 3 initiation in progressive MS.
Analysis · IMUX · Life Sciences
Immunic used a Regulation FD 8-K to host a Relapsing MS R&D Day, presenting detailed clinical and commercial data for its lead drug candidate, vidofludimus calcium. The presentation reaffirms that top-line data from the fully enrolled Phase 3 ENSURE-1 and ENSURE-2 trials are expected by the end of 2026, with an NDA submission targeted for mid-2027 and potential U.S. approval in 2028. The company also announced a Progressive MS R&D Day for November 5, 2026. This matters because the ENSURE readouts are the primary near-term value inflection point for the company, and the presentation provides the most comprehensive public update on the drug's dual mechanism, safety profile, and commercial positioning to date.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 30% of the 1973 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMUX was trading at $13.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $173.8M. The 52-week trading range was $5.06 to $17.43. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.